TrialObesity (Silver Spring, Md.)2023

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

Ildiko Lingvay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.